Ophthalmoplegia Market

Market Overview

The global ophthalmoplegia market size is registering a CAGR of 8.1% during the forecast period (2023-2031). The rise in the prevalence of diabetes and other neurological illnesses is fueling the expansion of the ophthalmoplegia market. In the United States, up to 35% of people have varicose veins.

Ophthalmoplegia is a disorder that causes paralysis or weakness of the muscles that move the eyes. This disorder can damage one or more of the six muscles that regulate eye movement. Ophthalmoplegia can cause various symptoms, including difficulty moving the eyes, double vision (diplopia), and eyelid drooping (ptosis). The intensity of symptoms varies based on the underlying reason and the muscles involved.

Furthermore, the growing older population and rising healthcare awareness and concerns are boosting the ophthalmoplegia market share. The growth of the ophthalmoplegia market is also driven by the government's initiatives in research and development. Furthermore, advancing new technical breakthroughs and revitalizing healthcare gadgets would provide significant prospects for the growth of the ophthalmoplegia market. As a result, the rising expense of the operation serves as a substantial impediment to the development of the ophthalmoplegia market.

Market Dynamics

Ophthalmoplegia Market Drivers

Increasing Prevalence of Underlying Conditions

Ophthalmoplegia is frequently a complication of another disorder, such as myasthenia gravis, multiple sclerosis, or thyroid eye disease. The rising global prevalence of these disorders may contribute to the ophthalmoplegia market trend. Myasthenia gravis is an autoimmune condition that causes muscle weakness and exhaustion. It can affect various muscles, including those involved in eye movement, resulting in Ophthalmoplegia. Myasthenia gravis is estimated to afflict approximately 20 in 100,000 people in the United States, according to the Myasthenia Gravis Foundation of America. Globally, the prevalence may vary by region. Myasthenia gravis frequently manifests as Ophthalmoplegia, affecting the eye movement muscles. As the prevalence of autoimmune illnesses such as myasthenia gravis rises, so does the probability of developing Ophthalmoplegia.

As the prevalence of illnesses associated with ophthalmoplegia rises, so does the number of people at risk of acquiring eye movement abnormalities. Healthcare systems must adjust to the growing burden of such illnesses, emphasizing the necessity of early diagnosis, specialist care, and the development of ophthalmoplegia-specific medications. Pharmaceutical companies and researchers may concentrate on developing medicines that address the unique needs of people suffering from ophthalmoplegia caused by autoimmune and neurological illnesses.

Ophthalmoplegia Market Restraints

High Healthcare costs

Diagnostic testing, continuing medical therapy, and prospective surgical options for ophthalmoplegia might be prohibitively expensive. High healthcare prices may prevent some people from receiving appropriate care. The United States had the OECD's largest per capita health expenditure in 2022, at USD 12,555. This is much greater than Switzerland's second-highest per capita health expenditure. Corticosteroids and immunosuppressants are popular medications used to treat MG. These medications can be costly and may rise as treatment continues. Depending on the treatment, a month's supply of prescription steroids can range from USD 30 to USD 170. Patients receiving immunosuppressive therapy must be monitored frequently for potential side effects and modifications to their treatment plan. This entails more medical appointments and costs.

Moreover, according to the NCBI, immunosuppressants typically cost between USD 10,000 and USD 14,000 a year. The cost of immunosuppression, on the other hand, can vary according to the month. A study titled "Economic Burden of Myasthenia Gravis in a US Managed Care Population" published in the Journal of Medical Economics (2019) analyzed the economic burden of MG. The study discovered that patients with MG had significantly higher mean yearly all-cause healthcare costs than a comparable control group. The expenditures associated with myasthenia gravis are determined by factors such as hospitalizations, drugs, diagnostic tests, and the requirement for specialist care, according to a review published in the Journal of Neurology (2020).

Ophthalmoplegia Market Opportunity

Advancement in Treatment Modalities

Ongoing research and development results in novel treatment approaches for the underlying illnesses that cause ophthalmoplegia, such as autoimmune disorders or genetic abnormalities. Gene therapy is a developing discipline that can address congenital abnormalities contributing to various eye illnesses, including ophthalmoplegia. LHON is a mitochondrial condition that can result in ophthalmoplegia and visual loss. Preclinical research in gene therapy, such as using adeno-associated virus (AAV) vectors to carry functional genes, shows promise. Gene therapy clinical trials for eye illnesses are now underway. A phase I/II clinical trial for LHON patients looking at the safety and efficacy of gene therapy, for example, found promising results in visual acuity improvement.

The amount of money invested in gene therapy research and development is growing. According to a McKinsey analysis, the worldwide gene therapy business is anticipated to increase dramatically in the following years, reaching billions of dollars. The Food and Drug Administration (FDA) of the United States has approved some gene treatments for ocular illnesses, providing regulatory support for novel treatment approaches. Advances in gene therapy and other related therapeutic techniques offer a substantial opportunity for creating focused and curative therapies for ophthalmoplegia caused by genetic abnormalities. Continued research and clinical studies are required to evaluate the safety and efficacy of these treatments, but progress shows a promising path for the creation of innovative medications.

Regional Analysis

North America Dominates the Global Market

The global ophthalmoplegia market analysis is conducted in North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.

North America is the most significant global ophthalmoplegia market shareholder and is estimated to grow at a CAGR of 8.3% over the forecast period. This is primarily due to the increased prevalence of varicose veins and the desire for minimally invasive treatments. The likelihood of getting varicose veins rises with age. The annual incidence rate for 18-34-year-olds is 0.73%, 1.23% for 35-44-year-olds, 1.62% for 45-54-year-olds, and 1.93% for 55-64-year-olds. Myasthenia gravis (MG) is a common disorder associated with ophthalmoplegia in North America. According to estimates, Myasthenia gravis affects 14 to 20 people per 100,000 in North America. This autoimmune condition can cause muscle weakness, weakening the muscles that regulate eye movement. According to the Census Bureau, the median age in the United States increased by 0.2 years between 2021 and 2022, reaching 38.9 years.

As a result, the US population is the oldest it has ever been. The number of people aged 65 and up in the United States is expected to nearly double from 52 million in 2018 to 95 million by 2060. The proportion of the population aged 65 and up will climb from 16 percent to 23 percent. The elderly population is also likely to push the market further during the forecast period. Furthermore, the regulatory framework in North America assures that innovative ophthalmoplegia treatments and therapies are subjected to rigorous examination and approval processes. The Food and Drug Administration (FDA) of the United States is crucial in examining the safety and efficacy of novel therapies that contribute to the overall quality of care. Ongoing research and development provide chances for introducing novel medicines that could revolutionize the ophthalmoplegia treatment landscape.

Europe is anticipated to exhibit a CAGR of 8.5% over the forecast period. According to ophthalmoplegia market insights, Europe is the world's second-largest market for ophthalmoplegia. The market is expanding due to increased government support and available cash for research. Furthermore, chronic progressive external ophthalmoplegia (CPEO) is a mitochondrial illness related to ophthalmoplegia that may be prevalent in European countries. The prevalence of mitochondrial abnormalities, including CPEO, varies, with estimates ranging from 1 in 5,000 to 1 in 10,000 people in different European countries.

In addition, European countries are actively involved in collaborative research projects and clinical trials focusing on neurological illnesses, including ophthalmoplegia. In Europe, patients might receive specialist care from multidisciplinary teams, including neurologists, geneticists, and ophthalmologists. Europe's modern healthcare infrastructure and regulatory framework create a favorable setting for launching novel therapeutics for ophthalmoplegia.

Asia-Pacific has the fastest-expanding ophthalmoplegia market due to an aging population and a rapidly developing medical industry. Asia-Pacific countries with advanced healthcare systems, like Japan and South Korea, have dedicated neurology and ophthalmology departments. However, research institutions in China and India are actively involved in genetic and molecular research on ophthalmoplegia to identify underlying causes and potential therapy possibilities. The region contributes to global research efforts with increasing publications on neurogenetic illnesses and ophthalmological conditions. Furthermore, patient advocacy groups in countries such as India and Singapore actively contribute to ophthalmoplegia awareness campaigns, support networks, and educational projects.

Segmental Analysis

The global ophthalmoplegia market is segmented based on type, application, and region.

The market is further divided into internuclear and external ophthalmoplegia based on type.

External ophthalmoplegia occupies the largest share of the market.

External Ophthalmoplegia

The paralysis or weakness of the muscles that control eye movement is called external ophthalmoplegia. This illness affects the extraocular muscles, which are in charge of moving the eyes in various directions. Various ailments, such as myasthenia gravis, mitochondrial disorders, and some neurological diseases, can cause external ophthalmoplegia. This word is frequently used in a broad sense to indicate weakness or paralysis of the eye muscles, and it can be related to a variety of disorders affecting neuromuscular transmission or muscle function. Its increased incidence may result in a more significant market volume for diagnostics, pharmaceuticals, and therapeutic devices, attracting more enterprises and propelling market expansion.

Internuclear Ophthalmoplegia

Internuclear ophthalmoplegia is an eye movement condition defined by decreased horizontal eye movement coordination caused by medial longitudinal fasciculus (MLF) impairment. INO is characterized by difficulty moving one eye horizontally, particularly while attempting to look to the side of the affected eye. A typical symptom is poor adduction (movement of the afflicted eye towards the nose), which results in horizontal diplopia. Demyelinating illnesses such as multiple sclerosis, brainstem lesions, or other neurological disorders affecting the MLF can produce internuclear ophthalmoplegia. The MLF's participation in INO reveals a particular pattern of eye movement dysfunction. It is frequently related to diseases affecting the brainstem and the integrity of the MLF.

The market can be bifurcated by application into hospitals and clinics and ambulatory clinics.

Hospitals and clinics are significant contributors to the market.

Hospital and Clinics

This sector comprises regular hospital settings and specialist clinics where clients receive various medical services, including ophthalmoplegia diagnosis, treatment, and procedures. Comprehensive ophthalmological services, neurology consultations, diagnostic imaging, and access to expert medical professionals are all provided by hospitals and clinics. The hospital industry dominates the market. The hospitals are outfitted with advanced and current technologies and competent healthcare staff, contributing to the segment's growth. Collaborations between hospitals and industry companies, on the other hand, are boosting growth by developing new surgical procedures.

Ambulatory Clinics

Ambulatory clinics, also known as outpatient clinics or ambulatory care centers, are medical facilities where patients can get medical care without being admitted to a hospital. Consultations, diagnostic testing, minor procedures, and follow-up appointments are all available at ambulatory clinics. Ambulatory clinics are a more convenient and accessible choice for people who need routine check-ups, monitoring, or less sophisticated therapies.

Recent Developments

• November 2023: Catiolanze® (a cationic emulsion of latanoprost 50 g/mL) by Santen was approved by the European Commission for reducing intraocular pressure in open-angle glaucoma and ocular hypertension.
• December 2023: Roche completed the acquisition of Carmot Therapeutics, which includes three clinical-stage assets with best-in-class promise in obesity and diabetes.